Compare GFL & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFL | CRL |
|---|---|---|
| Founded | 2007 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 10.9B |
| IPO Year | 2019 | 1999 |
| Metric | GFL | CRL |
|---|---|---|
| Price | $39.63 | $227.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $55.22 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 2.9M | 839.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $7.20 | $3.04 |
| P/E Ratio | $5.95 | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $33.33 | $144.26 |
| 52 Week High | $51.51 | $237.86 |
| Indicator | GFL | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 65.68 |
| Support Level | $38.60 | $218.39 |
| Resistance Level | $45.94 | $231.30 |
| Average True Range (ATR) | 1.18 | 8.55 |
| MACD | 0.07 | -0.78 |
| Stochastic Oscillator | 65.99 | 63.98 |
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.